One of the major problems with gene therapy today is
Introduction
Approximately 30% of cancer-related deaths are caused by local tumour failure suggesting that improving local control has the potential to improve the survival of onethird of all cancer patients. Many strategies to improve local tumour control are currently under investigation. Promising strategies seem to be those that combine existing therapeutic modalities with new developments including combining ionising irradiation with gene therapy. [1] [2] [3] [4] [5] [6] [7] [8] [9] This combination appears particularly promising as therapeutic genes can be chosen which have a radiosensitizing effect, thereby improving local tumour eradication. An example of this is the gene encoding the cytokine TNF␣. This protein has direct cytotoxic effects on some tumour cells, 10 can activate a cellular immune response 11 and can cause destruction of tumour microvasculature. 12 Moreover, TNF␣ shows synergistic or additive cell killing in combination with radiation. 13 A major obstacle in gene therapy is the specific targeting of therapeutic products to the tumour cell while concurrently leaving normal tissue unaffected. Tumourspecific gene expression can be achieved either by targeting the delivery system (transductional targeting) or a significant increase of TNF␣ production of 42% (P Ͻ by limiting expression of the gene to the tumour cells (transcriptional targeting). One way to address the latter strategy is the use of radiation-inducible promoters to spatially and temporally target gene expression. [1] [2] [3] [4] [5] [6] [7] [8] [9] For example, when the radio-responsive Egr1 promoter was used to regulate expression of TNF␣ in human xenografts, an increase in tumour cure was noted without increasing normal tissue toxicity. 2, 3 The combination of gene therapy with radiotherapy thus appears to be a promising approach to increase the therapeutic ratio of cancer therapy. However, an important limitation in this strategy remains the lack of specificity of the vectors used to deliver the therapeutic gene to the tumour.
In our laboratory, we use strictly anaerobic apathogenic Clostridium spp. to deliver the therapeutic proteins to the tumour. When Clostridium spores are injected intravenously into a tumour-bearing animal, a selective colonisation of hypoxic/necrotic tissues, with more than 10 8 CFU/g tumour is obtained.
14 Moreover, the bacteria can be genetically modified to produce and secrete therapeutic proteins. [14] [15] [16] [17] [18] To further increase the specificity of cytotoxic protein delivery and to achieve temporal control of protein expression, we have investigated the use of prokaryotic radio-induced promoters to control gene expression in Clostridium. 19, 20 Via the use of a reporter gene, we demonstrated that the recA gene, belonging to the SOS-repair system in bacteria, is induced by ionising irradiation.
In this report, we investigated whether ionising irradiation could increase the production of TNF␣ in Clostridium in the case of TNF␣-cDNA placed under the control of the recA promoter. We measured the amount of TNF␣ production after single-dose irradiation and tested if gene activation could be repeated with a second radiation dose.
Results
ELISA analysis was used to quantify TNF␣ secretion by recombinant clostridia containing mTNF␣-cDNA on the shuttle plasmid pIMP (Figure 1 ). Figure 2 shows the induction of TNF␣ production in recombinant clostridia containing the pIMP-recA-TNF␣ vector after a single dose of 2 Gy. The data are expressed as fold increase in secretion compared with unirradiated bacteria containing the same plasmid (see Materials and methods). A single dose of 2 Gy showed a 1.44 (± 0.15 s.d.) fold increase of TNF␣ production compared with unirradiated bacteria (P Ͻ 0.05, Student's t test, two-paired samples for means). This maximum induction of 44% was observed 3.5 h after irradiation and declined thereafter. At earlier time intervals, no significant increase in TNF␣ secretion was seen, but there was a trend to increase secretion reaching a significant level after 3.5 h. These data demonstrate that the recA promoter can give a significant increase of TNF␣ production by recombinant clostridia after a single dose of 2 Gy.
In patient treatments, radiotherapy is typically given in multiple fractionated doses. Therefore, we examined if the radio-inducible promoter could be reactivated with a second irradiation. The data presented in Figure 3A represent the induction of TNF␣ 3 h after a first dose of 2 Gy. A 1.33 to 1.36 (± 0.11-0.12 s.d.)-fold increase was seen, which corresponds with the 37% increase in TNF␣ production seen in Figure 2 . TNF␣ induction 3 h after a second dose of 2 Gy for sample [a] and a mock irradiation for sample [b] is shown in Figure 3B . The higher level of TNF␣ production seen after 2 × 2 Gy fractions in comparison to 1 × 2 Gy, indicated that the promoter can be reactivated at a clinically relevant dose. Overall, two fractions of 2 Gy resulted in a 1.59 (± 0.14 s.d.)-fold increase in TNF␣ production which was significant, compared with no irradiation (P Ͻ 0.02, Student's t test) and with a single dose of irradiation (1. Figure 3B ) is the remaining induction effect from the first irradiation indicating that at this time interval, an induction of TNF␣ secretion as a result of the first irradiation remains. These data indicate that the recA promoter in Clostridium can be reactivated by a second dose of radiotherapy.
Discussion
Several previous studies have employed radiotherapy to spatially and temporally control gene expression using the Egr1 promoter in almost each case. [1] [2] [3] [4] [5] [6] [7] [8] [9] However, in most studies induction of gene expression is achieved using total doses of 20-50 Gy sometimes using fractions up to 5 Gy. 3, 12 Since a dose of 5 Gy is not used in a curative treatment setting, this high dose to achieve induction can be a limiting factor. Since the eukaryotic Egr1 promoter is not functional in bacteria, we investigated the use of a prokaryotic radio-inducible promoter. In our study, significant induction of the recA promoter is achieved at only 2 Gy, which makes it more relevant for clinical use. A single dose of 2 Gy gives an increase of TNF␣ secretion of 44% 3.5 h after radiotherapy (Figure 2 Figure 3B ) there is still a 17% increase of extracellular TNF␣ activity, although not significant. This implies that of the 59% induction we measured after the second irradiation (sample [a]), 42% is the actual result of repeated gene activation and the residual 17% is still the effect of the first irradiation. This 42% induction after a second dose is in the range of induction values of 33-36% (± 11-12%) obtained after the first dose.
Figure 3 Induction of mTNF␣ in recombinant clostridia after 2 × 2 Gy. (A) Fold increase of mTNF␣ secreted by C. acetobutylicum 3 h after a first dose of 2 Gy ([a] and [b]). (B) Fold increase of mTNF␣ secreted by C. acetobutylicum after a second dose of 2 Gy ([a]) in comparison with one dose of 2 Gy ([b]), 6 h after the first irradiation
These data provide the proof of principle that the recA promoter in Clostridium can be efficiently reactivated by a second dose of radiotherapy and that the degree of induction remains more or less the same as compared with single dose irradiation.
This will be important in achieving controlled high levels of therapeutic gene expression in the clinical setting. In patient treatments, daily radiation fractions would be capable of activating the radio-inducible promoter leading to a daily increase of TNF␣ of 44% locally in the tumour.
There is, however, a rapid decline in promoter activity. A maximum level of induction is achieved after 3.5 h, which drops back to half after 6 h. When we compared these kinetics with those of the Egr1 promoter, the kinetics are quite similar. 4 Joki et al 4 measured a maximum induction 1-3 h after a single dose of 20 Gy, and this induction dropped to about 50% after 6 h, and to basal level after 12 h. Notwithstanding these rapid promoter kinetics, they proved a therapeutic benefit in vitro when using their radio-induced promoter.
Unirradiated clostridia produce TNF␣ because of basal activity of the recA promoter. Maximum levels of 6200 pg/ml TNF␣ were measured in untreated samples. This basal activity can be reduced by inserting an additional Cheo box in the promoter region. 21 After irradiation of the recombinant clostridia, concentrations of 8800 pg/ml of mTNF␣ can be achieved (data not shown). Previous studies have reported that doses of hTNF␣ ranging between 10 and 1000 U/ml are cytotoxic to human tumour cell lines. 13 Since mTNF␣ has a specific activity of about 10 8 U/mg (data not shown), the concentration of 8800 pg/ml corresponds to 880 U/ml. This concentration should be sufficiently high enough to result in a cytotoxic Gene Therapy effect on human tumour cells indicating that Clostridium is capable of producing sufficient amounts of TNF␣ to have an antitumoral effect.
In vitro and in vivo experiments are planned to prove that an additional increase in TNF␣ of 44% can lead to an increase in cell kill. However, when we look at some dose-response curves for TNF␣, we can expect that an increase in TNF␣ concentration of 44% can lead to an increase in cell kill. 5 Spatial and temporal control of gene expression by ionising irradiation is a relatively new and promising concept. The system we describe exploits the benefits of a tumour-specific vector in combination with radiotherapy which triggers and increases gene expression. Since therapeutic agents such as TNF␣ can be highly toxic, temporal control of protein expression can be very beneficial. In patient treatments, physicians will know from what time-point TNF␣ will be present in the tumour. TNF␣ will be expressed locally in the tumour, mainly in the hypoxic regions. However, TNF␣ shows a reduced cytotoxicity to hypoxic cells, because the mechanism of direct cytotoxicity may involve hydroxyl radical production. 22 However, since TNF␣ is a small and compact molecule, it will diffuse and will also reach the more oxygenated cells. Moreover, in addition to a direct cytotoxic effect, TNF␣ also has an indirect antitumour effect. In combination with irradiation, TNF␣ causes occlusion of tumour microvessels, without significant normal tissue damage. 12 TNF␣ gene therapy targeted by ionising radiation results in an amplified bystander effect, resulting in extensive necrosis distal to thrombosed tumour vessels.
Fractionated radiotherapy can provide a method to repeat gene induction resulting in enhanced and prolonged gene expression. Since anaerobic bacteria like Clostridium may colonise other hypoxic/necrotic tissues besides tumoral, such as for instance abscesses and infarcted tissues, spatial control of gene expression would be advantageous. Further benefiting the treatment plan, Clostridium can be completely eradicated by the administration of antibiotics, 23 suggesting that complete control of gene expression can be obtained; radiation will switch it on, and, if necessary, antibiotics can switch it off.
The use of a prokaryotic radio-induced promoter to temporally and spatially control gene expression is not only limited to Clostridium-mediated therapy for cancer. Recently, genetically engineered Salmonella 24, 25 and Bifidobacterium longum 26 have shown that these bacteria also have the desirable properties of an antitumour vector. Both strains provide selective colonisation of solid tumours and can express proteins. Since the SOS-repair system in bacteria is highly conserved, the recA promoter can probably act as a radio-induced promoter in other bacteria to control gene expression after radiotherapy. The combination of radiotherapy, which preferentially kills well-oxygenated cells, with Clostridium (or analogous)-mediated protein delivery, which targets the hypoxic cells, provides new possibilities for future cancer therapy.
Materials and methods
Bacterial strains, media and culture conditions Clostridium acetobutylicum DSM792 was grown in 2 × YT medium 27 at 37°C in an anaerobic incubator (model 1024; 29 The E. coli/C. acetobutylicum shuttle plasmid pIMP was used as cloning vector. 30 Media were supplemented, when applicable, with erythromycin (25 g/ml) or ampicillin (50 g/ml).
Plasmid construction, transformation procedures
The recA promoter was isolated as previously described. 20 The mTNF␣ cDNA was available on plasmid pIG2mTNF (Innogenetics, Gent, Belgium). The signal sequence of the eglA promoter was used to obtain secretion of TNF␣. 15 The promoter and signal sequence were cloned upstream of the mTNF␣ cDNA after introducing unique NcoI and KasI restriction sites in the pIMP vector using the 'Quickchange Site-directed Mutagenesis kit' (Stratagene, La Jolla, CA, USA) ( Figure 1 ).
E. coli was transformed using chemically competent cells obtained with the RbCl method. Transformation of C. acetobutylicum DSM792 was carried out as recently published. 31 All general DNA manipulations in E. coli were carried out as described by Sambrook et al. 28 
Irradiation
Bacteria were grown until early log phase (OD 600nm = ± 0.3). At this time-point cultures were divided into two sets, one of which was exposed to radiation while the other was mock-irradiated and used as a control. Bacteria were exposed to 2 Gy with a 60 Cobalt unit at a dose rate of 0.9 Gy/min. After irradiation, bacteria were incubated anaerobically at 37°C and samples were taken at different time intervals after exposure.
For repetitive gene activation, bacteria were grown to early log phase. Cultures were then divided into three flasks and exposed to 2 Gy (flasks [a] and [b]) or mockirradiated (flask [c]). Three hours after radiation, the culture was centrifuged (10 min, 10 000 r.p.m., 4°C) and supernatant was taken for analysis. An interval of 3 h after irradiation was chosen because at this time-point the highest degree of induction was seen. Because in batch culture bacteria already reach stationary phase after ± 5 h, repetitive gene activation could not be tested at greater time intervals. Therefore, we chose to resuspend the bacteria in fresh medium to have actively dividing bacteria. Similarly, in the clinical setting, bacteria gain a continuous supply of nutrients which will result in a continuous growth of viable cells. The pellet was resuspended in fresh 2 × YT medium and allowed to regrow for 40 min. Flask [a] was irradiated a second time with 2 Gy, while flasks [b] and [c] were mock-irradiated. Again, 3 h after irradiation and incubation at 37°C, cultures were centrifuged and supernatant was sampled for analysis.
Each experiment was independently repeated three times.
Analysis of mTNF␣ production
The amount of TNF␣ secreted by recombinant clostridia was quantified using ELISA. Supernatant taken from irradiated and non-irradiated cultures was diluted 10-fold in phosphate-buffered saline plus 7.5% bovine serum albumin and 100 l aliquots were put in a 96-well microtiter plate. Further manipulations were done according to the manufacturer's protocol (DiaMed EuroGen, Tessenderlo, Belgium).
Concentrations of secreted mTNF␣ were calculated and compared for the irradiated and non-irradiated cultures. The level of radio-induced TNF␣ production was expressed as fold increase in mTNF␣ concentration of irradiated samples compared with the corresponding non-irradiated samples.
